FY2025 · period end Dec '25 · from the 10-K filed Feb 24, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $65.01B |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001104659-26-067509 | May 26, 2026 | May 28, 2026 | May 28, 2026 20:15 UTC | EDGAR |
| 8-K | 0001628280-26-037738 | May 22, 2026 | May 22, 2026 | May 22, 2026 20:21 UTC | EDGAR |
| 10-Q | 0001628280-26-029802 | Mar 31, 2026 | May 4, 2026 | May 4, 2026 20:10 UTC | EDGAR |
| 8-K | 0001104659-26-052081 | Apr 30, 2026 | Apr 30, 2026 | Apr 30, 2026 10:53 UTC | EDGAR |
| 10-K | 0000310158-26-000063 | Dec 31, 2025 | Feb 24, 2026 | Feb 24, 2026 21:15 UTC | EDGAR |
| 8-K | 0001104659-26-009495 | Feb 3, 2026 | Feb 3, 2026 | Feb 3, 2026 11:38 UTC | EDGAR |
| 8-K | 0001628280-25-055388 | Dec 4, 2025 | Dec 4, 2025 | Dec 4, 2025 21:36 UTC | EDGAR |
| 10-Q | 0000310158-25-000059 | Sep 30, 2025 | Nov 5, 2025 | Nov 5, 2025 21:08 UTC | EDGAR |
Direct links to SEC EDGAR. MRK has additional filings available on the SEC site.
6 numbers Merck & Co., Inc. later changed — same XBRL tag, both filings linked.
Net Income (Loss) Available to Common Stockholders, Basic·Q3 2009
Major restatementwas$477M
Revised up in a 10-Q.
Net Income (Loss) Attributable to Parent·Q3 2009
Major restatementwas$515M
Revised up in a 10-Q. Any P/E built on the original was 85.0% too high.
Net Income (Loss) Available to Common Stockholders, Basic·Q2 2009
Major restatementwas$633M
Revised up in a 10-Q.
Net Income (Loss) Attributable to Parent·Q2 2009
Major restatementwas$671M
Revised up in a 10-Q. Any P/E built on the original was 56.9% too high.
Stockholders' Equity Attributable to Parent·As of Dec 31, 2008
Major restatementwas$10.5B
Revised up in a 10-K.
Assets·As of Dec 31, 2008
Major restatementwas$28.1B
Revised up in a 10-K.
MRK is not the only one.
See every restatement we've found across the market — or get an alert the next time MRK revises a number.
Restatements are detected by comparing every vintage of a fact across all of Merck & Co., Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows MRK's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Merck & Co., Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on MRK yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on MRK and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| $60.12B |
| $59.28B |
| $48.70B |
| Gross Profit | $48.63B | $48.98B | $43.99B | $41.87B | $35.08B |
|---|
| Operating Income | — | — | — | — | — |
|---|
| Net Income | $18.25B | $17.12B | $0.36B | $14.52B | $12.35B |
|---|
| EPS (Diluted) | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 |
|---|
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $136.87B | $117.11B | $106.67B | $109.16B | $105.69B |
| Total Liabilities | — | — | — | — | — |
| Stockholders' Equity | $52.66B | $46.37B | $37.63B | $46.06B | $38.26B |
| Cash & Equivalents | $14.56B | $13.32B | $6.91B | $12.77B | $8.17B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $16.47B | $21.47B | $13.01B | $19.09B | — |
| Capital Expenditures | $4.11B | $3.37B | $3.86B | $4.39B | $4.45B |
| Free Cash Flow | $12.36B | $18.10B | $9.14B | $14.71B | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 74.8% | 76.3% | 73.2% | 70.6% | 72.0% |
| Operating Margin | 0.3% | 0.2% | 0.0% | 0.2% | 0.2% |
| Net Margin | 0.3% | 0.3% | 0.0% | 0.2% | 0.3% |
| Return on Equity | 36.9% | 40.8% | 0.9% | 34.4% | 38.8% |
| Return on Assets | 14.4% | 15.3% | 0.3% | 13.5% | 12.5% |
| Debt / Equity | 0.93× | 0.80× | 0.93× | 0.66× | 0.76× |
